argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Cellevolve Bio, Inc. ("the Company" or "Cellevolve"), a development and commercialization platform company focused on cell therapies, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback